Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2024-08-06 Earnings Release
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec provides guidance update
Earnings Release Classification · 1% confidence The document is titled "Evotec provides guidance update" and details revisions to the fiscal year 2024 guidance for Revenues, R&D expenditures, and Adjusted EBITDA. It discusses H1 2024 performance and outlines expectations for H2 2024. This content—a company providing updated financial outlook and performance commentary—is characteristic of an Earnings Release (ER) or a Management Discussion & Analysis (MDA). However, the text explicitly states, "Evotec will release its detailed results for the first half year 2024 on 14 August." This indicates the current document is a preliminary announcement or update focused solely on guidance revision, not the full detailed report. Since it is an announcement of financial performance highlights and guidance changes, it fits best under Earnings Release (ER). It is not a full transcript (CT), a full annual report (10-K), or a comprehensive interim report (IR), as the detailed H1 results are scheduled for a later date. H1 2024
2024-08-06 English
Evotec SE provides guidance update
Management Reports Classification · 1% confidence The document is explicitly labeled as an 'Ad-hoc' release dated August 6, 2024, and states it is a 'Disclosure of an inside information acc. to Article 17 MAR'. The content details a refinement of the guidance for the fiscal year 2024, specifically updating expected Group revenues, R&D expenditures, and Adjusted EBITDA. This type of immediate, material financial update, often released outside of standard quarterly reporting cycles, is best classified as an Earnings Release (ER) as it conveys key financial performance expectations and changes. Although it is an update rather than a full report, it functions as an immediate release of financial performance indicators, fitting the 'ER' definition better than a general 'RNS' or 'RPA'. The document length is short, but it contains the core financial guidance changes, not just an announcement that a report is available.
2024-08-06 English
Company Presentation August 2024 (English)
Investor Presentation Classification · 1% confidence The document is explicitly titled 'General company presentation' and contains extensive slides detailing the company's strategy, R&D pipeline, operational capabilities (Shared R&D, Just - Evotec Biologics), financial performance summary for 2023, 2024 guidance, strategic priorities, and management/board structure. This format, rich in visuals and strategic narrative, is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a brief announcement (RPA/RNS). It contains financial data but is structured as a presentation, differentiating it from a formal Interim Report (IR) or Earnings Release (ER).
2024-08-01 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Evotec SE: Release according to Article 40, Section 1 of the WpHG' and explicitly contains a section titled 'Notification of Major Holdings'. It details changes in voting rights percentages (e.g., from 9.38% to 8.90%) held by T. Rowe Price Group, Inc. and its subsidiaries, crossing or reaching specific thresholds as defined by German securities law (WpHG). This content directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels. This matches the definition for Major Shareholding Notification (Code: MRQ). It is not an AGM-R, 10-K, ER, or IR, as it focuses purely on ownership changes, not comprehensive financial results or meeting materials.
2024-07-23 English
Correction of a release from 11/07/2024, 14:16 CET/CEST - Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a 'Correction of a release' concerning the 'Total Voting Rights' and references a 'Conditional capital increase' under German Securities Trading Act (WpHG). This type of announcement, detailing changes in the total number of voting rights, directly relates to the company's capital structure and shareholder rights. Reviewing the definitions: - AGM-R: Not an AGM presentation. - 10-K/IR: Not a full annual or interim financial report. - ER/MDA: Not an earnings release or management discussion. - DVA (Declaration of Voting Results & Voting Rights Announcements): This category specifically covers announcements related to voting rights. The document explicitly states 'Total Voting Rights Announcement' and provides the new total number of voting rights (177,553,385). - CAP (Capital/Financing Update): While related to capital, DVA is more specific for voting rights totals. - SHA (Share Issue/Capital Change): This is related, but DVA is the precise category for the official notification of the total number of voting rights outstanding. Therefore, the most accurate classification is DVA (Declaration of Voting Results & Voting Rights Announcements). The document is short and is a direct regulatory announcement, not a summary or a full report.
2024-07-11 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Evotec SE: Release according to Article 41 of the WpHG' and specifically announces the 'Publication of new total number of voting rights'. It details a 'Conditional capital increase' and provides the 'New total number of voting rights' (177,551,165). This type of mandatory disclosure regarding changes in the total number of shares/voting rights, often triggered by capital structure events like conditional capital increases under German law (WpHG Article 41), is a regulatory announcement. Since there is no specific category for 'Total Voting Rights Announcement' and it is a mandatory regulatory disclosure that doesn't fit 10-K, ER, or IR, the most appropriate classification is the general regulatory filing category, RNS. It is not a DVA (which is for voting results) or SHA (which is for the issuance itself, though related, this is the notification of the resulting total count). Given the nature of the mandatory disclosure via EQS News, RNS is the best fit.
2024-07-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.